Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia

Konstantinos Dimitropoulos
Stavros Gravas
Department of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece

Abstract: Treatment of male lower urinary tract symptoms (LUTS) has traditionally focused on the management of benign prostatic obstruction, but the contribution of bladder dysfunction has been recently recognized. Therefore, it is well understood that LUTS have multifactorial etiology and often occur in clusters and not in isolation. Voiding LUTS are highly prevalent in men, but storage LUTS have been proved to be more bothersome. α₁-Blockers are the most widely used pharmacologic agents for the treatment of symptoms relating to benign prostatic enlargement due to benign prostatic hyperplasia (BPH), while antimuscarinics are the drug class of choice for overactive bladder symptoms. A combination of the two drug classes would be a reasonable approach to treat men with both storage and voiding symptoms, and several short-term studies have proved the efficacy and safety of different combinations with an α₁-blocker and an antimuscarinic. Following previous studies on the separate administration of solifenacin and tamsulosin, a fixed-dose combination tablet of tamsulosin oral controlled absorption system (OCAS) 0.4 mg and solifenacin succinate 6 mg has been recently introduced, and the current review evaluates the available data on the use of this fixed-dose combination in the treatment of LUTS in men with BPH.

Keywords: benign prostatic obstruction, lower urinary tract symptoms, overactive bladder, fixed-dose combination, benign prostatic hyperplasia, tamsulosin, solifenacin

Introduction

Lower urinary tract symptoms (LUTS) are common in men over 45 years of age, and are divided into storage (urinary daytime frequency, nocturia, urinary urgency, incontinence), voiding (urinary hesitancy, slow stream, straining or spraying, intermittent stream, terminal dribbling), and postmicturition (feeling of incomplete emptying, postmicturition dribbling) symptoms. It has been found that 71% of male patients report symptoms from at least one LUTS group, and one-third of men all three groups. A large epidemiological study conducted in five countries revealed that approximately two-thirds of men report at least one LUTS complaint. Storage group symptoms are commonly linked with overactive bladder (OAB), based on the current definitions of International Incontinence Society.

In men, LUTS have been historically attributed to bladder outlet obstruction (BOO) as a result of benign prostatic obstruction (BPO), which is often associated with benign prostatic enlargement (BPE) resulting from the histologic condition of benign prostatic hyperplasia (BPH). Similar to LUTS, BPE is age-related; only 18% of 40-year-old men suffer from prostatic enlargement, while 50% of 50-year-old men and 90% of men in their 90s report symptoms related to BPE/BPH. As a result, pharmacological and surgical interventions mainly aimed to control BPE/BPO. However, it has to be noted...
that BPH/BOO is not the only cause of LUTS, as several other conditions have been proved to participate in LUTS pathogenetic pathways. OAB has also been typically believed to be more prevalent in women, but population-based prevalence studies showed that OAB symptoms affect up to 17% of the population, with age-related increases in both men and women. While voiding symptoms are the most prevalent ones in men, storage LUTS have been proved to cause a greater impact on the quality of life and embarrass and bother patients the most. The main players in the arena of medical treatment of male LUTS related to prostatic enlargement are α₁-blockers and 5-alpha reductase inhibitors (5aRIs) either as monotherapy or as combination. However, the storage component of LUTS is commonly undertreated, as these widely used agents for voiding symptoms may fail to control OAB-like symptoms, and antimuscarinics are infrequently prescribed in men with BPE/BOO due to a widely prevalent, yet unproved, fear of post-void residual (PVR) increase, or, worse, acute urinary retention (AUR).11–16

Since a significant number of BPE/BPH patients suffer from both voiding and storage symptoms, a combination of drugs aiming at prostate and bladder would be a reasonable approach to control or alleviate symptoms. This was the rationale of several studies that evaluated the combined use of various α₁-blockers and muscarinic receptor antagonists as initial or add-on treatment in men with OAB and BPE/BPO. The reported results led the European Association of Urology to add a treatment guideline that combination treatment with α₁-blocker and antimuscarinic may be used in patients with bothersome moderate-to-severe nonneurogenic LUTS, if storage symptoms relief has been insufficient with monotherapy with either drug. Even though PVR increase was found to be clinically insignificant and risk for AUR was low, combination treatment is recommended with caution in men with possible BOO.2

A fixed-dose combination (FDC) tablet of tamsulosin oral controlled absorption system (OCAS) 0.4 mg and solifenacin succinate 6 mg (Vesomni™, Astellas Pharma Europe BV, Leiden, the Netherlands) has been recently authorized for use in men with moderate-to-severe storage symptoms and voiding symptoms associated with BPH, not adequately responding to treatment with monotherapy. This study aims to review the literature about the use of tamsulosin/solifenacin FDC in controlling voiding and storage LUTS in men with BPE due to BPH.

A structured search was performed using articles in English language published in PubMed/Medline and Cochrane databases between 2000 and October 1, 2014, including the search terms “lower urinary tract symptoms”, “benign prostatic hyperplasia”, “solifenacin”, “tamsulosin”, and “fixed dose combination”. Articles were systematically retrieved, selected, assessed, and summarized for this review.

**Overview of tamsulosin**

Noradrenaline-mediated contraction of prostate smooth muscles has been proposed to be implicated in the pathogenesis of BOO as a result of BPE/BPH. Moreover, it has been proved that human prostate smooth muscles contraction is driven almost exclusively by α₁-adrenoceptors. As a result, α₁-blockers have been long used to alleviate BPH-related LUTS (BPH-LUTS) by blocking prostatic smooth muscle contraction and reducing induced BOO. However, urodynamic findings in men treated with α₁-adrenergic antagonists for BPH-LUTS have shown that despite symptoms improvement, bladder obstruction was insignificantly altered by α₁-blockers’ action. Thus, other mechanisms of action may be relevant, such as mediation of chronic ischemia-induced LUTS by improving blood perfusion in prostate and bladder neck.

Tamsulosin has been proven to show selectivity for α₁A- and α₁D-adrenoceptors of prostate and bladder neck, and good affinity for α₁L-variant of α₁A-receptors.7 Bioavailability of tamsulosin reaches 90%, and when administered, it occupies almost 80% of prostate α₁-adrenoceptors within 4 hours, and remains bound to 44% of receptors at 24 hours postadministration. Its peak plasma concentration after administration (Cₘₐₓ) is 11.3 ng/mL with a median time to Cₘₐₓ(tₘₐₓ) of 6 hours; mean elimination half-life (t₁/₂) is 13.5 hours, while mean area under the serum concentration–time curve after single dose (AUC) is 187.2 ng⋅h/mL. In addition, tamsulosin can be safely used in patients with mild-to-moderate renal or hepatic impairment.

The most frequently reported complications related to α₁-blockers use comprise asthenia, dizziness, and orthostatic hypotension. Tamsulosin has been proved to have a very good cardiovascular tolerability. This was originally attributed to its α₁A-adrenoceptors selectivity, therefore avoiding cardiovascular side effects related to the blockade of all three types of α₁-receptors and especially α₁B ones which have an increased role in the blood vessels of the elderly. However, this was not fully confirmed by studies findings. In addition, the OCAS tamsulosin formulation was independent of fed and fasted states and exhibited a somewhat longer tₘₐₓ and markedly lower Cₘₐₓ in single-dose studies and a lower ratio between the peak and 24-hour concentrations, resulting in a much safer cardiovascular profile. Tamsulosin reaches
significantly higher concentrations in prostate rather than in plasma, further reducing its vascular side effects.\textsuperscript{30,31}

Ejaculatory disorders represent another category of tamsulosin side effects. Originally, it was proposed that tamsulosin induced retrograde ejaculation by significantly reducing bladder obstruction. However, studies have shown that it is a form of anejaculation,\textsuperscript{32,33} possibly mediated by \( \alpha_1 \)-blockade.\textsuperscript{32} Intraoperative floppy iris syndrome is a complication of cataract surgery linked with \( \alpha_1 \)-blockers treatment, mainly tamsulosin;\textsuperscript{14} however, the exact pathogenetic mechanism has not been clarified.

**Overview of solifenacin**

Acetylcholine resembles the neurotransmitter that mainly mediates human bladder contraction. It acts on all five subtypes of G-proteins-coupled muscarinic receptors, with M2 and M3 receptors being the most frequently detected ones in urothelium, interstitial and nerve cells, and detrusor smooth muscle.\textsuperscript{35} In healthy bladder, M3 receptors are the most important ones for detrusor contraction, while M2 receptors activation seems to further enhance the contractile response mediated by M3 receptors.\textsuperscript{36,37} Moreover, M3 receptors have been found to regulate neurotransmitter release in presynaptic nerve terminals, while the presence of both M2 and M3 receptors in urothelium/suburothelium has been proposed to be implicated in various clinical bladder syndrome pathogeneses.\textsuperscript{35}

Thus, antimuscarinics use aims to reduce spontaneous detrusor activity in storage phase by the combined decrease of contractions frequency and intensity.\textsuperscript{35,38} In addition, it has been found that antimuscarinics also increase bladder capacity by inhibiting bladder afferent mechanisms during filling.\textsuperscript{19} Succinate salt of solifenacin is a relatively new antimuscarinic agent. Solifenacin binds to all types of muscarinic receptors and reaches peak concentration 3–8 hours after per os administration.\textsuperscript{40,41} Similar to tamsulosin, solifenacin has high bioavailability that reaches 90%, independently of fasting state or not. Steady-state \( C_{\text{max}} \) for solifenacin 5 and 10 mg is 32.3 and 62.9 ng/mL, respectively, with a \( t_{\text{max}} \) ranging within 3–8 hours. Mean \( t_{\frac{1}{2}} \) and AUC for 5 and 10 mg doses are 64.4 and 60.9 hours, and 637 and 1,236 ng⋅h/mL, respectively.\textsuperscript{42} About 2–4 weeks of once-daily administration are required to obtain full clinical effect. Solifenacin should be carefully used in patients with severe renal and moderate hepatic impairment or receiving CYP3A4 inhibitors, such as ketoconazole.

Compared to other antimuscarinics, solifenacin seems to be the more bladder-specific one, thus reducing other specific-organ-related side effects.\textsuperscript{35,40} Although solifenacin has been proved to have higher affinity for M3 over M2 receptors and lower affinity for M1 and M5 receptors than the vast majority of antimuscarinics, this does not fully explain its bladder specificity, therefore necessitating further research.\textsuperscript{35,40} As with other antimuscarinic agents in use, the more frequent adverse events of solifenacin comprise dry mouth (due to M3 receptor antagonism in salivary glands), constipation (as M3 receptors mainly mediate dry mouth), and blurred vision (since M3 receptors are found in human ciliary cells and iris sphincter muscles).\textsuperscript{35} Adverse events frequency seems to be dose-related for solifenacin, with 5 mg being the safest dose. Risk for cardiac events, such as increased heart rate or QT interval prolongation is generally minimally affected when recommended doses are used.

As a tertiary amine, solifenacin can cross blood–brain barrier and bind to numerous M1 receptors located in neocortex, hippocampus, and neostriatum.\textsuperscript{35,40} Expected central nervous system side effects comprise headache, somnolence, cognitive function impairment, and dizziness; however, an established causal relationship between solifenacin treatment and central nervous system adverse reactions has not been proved yet.\textsuperscript{35,40} Owing to their inhibitory effect on bladder detrusor contraction, antimuscarinics have been proven to increase PVR, although research has shown that induced increase is minimal, especially in men without BOO. Studies using monotherapy with tolterodine as an antimuscarinic agent in men with BOO, as well as studies using a combination of antimuscarinics, including solifenacin, with \( \alpha_1 \)-blockers have shown minimal AUR risk in BOO patients with OAB symptoms.\textsuperscript{35,43} Nevertheless, administration of solifenacin in men with BOO seems to be safe; however, it should be performed with caution, with regular patients’ follow-up and PVR reevaluation.

**Overview of studies on tamsulosin plus solifenacin combinations**

Several studies have evaluated the efficacy and safety of combined tamsulosin and solifenacin for the management of storage and voiding LUTS in men with BPE/BPH. Table 1 presents the design, primary and secondary end points, measured parameters, and final results of these studies. The reported therapeutic effects of tamsulosin and solifenacin in these studies were, to a certain degree, indicative of the action offered by FDC tablets and triggered the development of FDC. It should be underlined that these studies were characterized by a short follow-up, while patients enrolled had low baseline PVR.
Table 1 Characteristics and results of studies on combination/add-on treatment with tamsulosin and solifenacin

<table>
<thead>
<tr>
<th>Author</th>
<th>Type of study</th>
<th>Number of participants</th>
<th>Trial design</th>
<th>Outcome measures</th>
<th>Efficacy of TAM + SOL*</th>
<th>Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kaplan et al. (VICTOR)</td>
<td>12-week, double-blind, randomized, placebo-controlled</td>
<td>397</td>
<td>Run-in period: 4 weeks of TAM 0.4 mg&lt;sup&gt;†&lt;/sup&gt; 12 weeks of TAM 0.4 mg + SOL 5 mg (202 pts) or TAM 0.4 mg + pbo (195 pts)</td>
<td>PVR, Q&lt;sub&gt;max&lt;/sub&gt;, daily micturitions, daily urgency episodes, PPBC, UPS, IPSS</td>
<td>vs TAM + pbo; Greater reduction in urgency</td>
<td>Adverse events rate was low, with dry mouth to be the most frequent (7% vs 3%) AUR in TAM + SOL (7%)</td>
</tr>
<tr>
<td>Masumori et al.</td>
<td>12-week, nonrandomized, no placebo</td>
<td>48</td>
<td>≥4 weeks of TAM 0.2 mg before enrollment 12 weeks of TAM 0.2 mg + SOL 5 (31 pts) or 2.5 mg (17 pts)</td>
<td>PVR, Q&lt;sub&gt;max&lt;/sub&gt;, IPSS, QoL index, OABSS</td>
<td>IPSS, storage IPSS, QoL, and OABSS improved after SOL add-on</td>
<td>No AUR; No difference in PVR</td>
</tr>
<tr>
<td>Yamaguchi et al. (ASSIST)</td>
<td>12-week, double-blind, randomized, placebo-controlled</td>
<td>638</td>
<td>Run-in period: 2 weeks of TAM 0.2 mg or pbo 12 weeks of TAM 0.2 mg + pbo (215 pts), or TAM 0.2 mg + SOL 2.5 mg (210 pts), or TAM 0.2 mg + 5 mg (213 pts)</td>
<td>PVR, Q&lt;sub&gt;max&lt;/sub&gt;, daily micturitions, nocturia episodes, daily urgency episodes, daily urgency incontinence episodes, IPSS, QoL, OABSS</td>
<td>vs TAM + pbo; Reduction in frequency (for both SOL 2.5 and 5 mg), urgency (for SOL 5 mg), nocturia, and urgency incontinence improvements in total IPSS, storage IPSS (for both SOL 2.5 and 5 mg), voiding IPSS, QoL, and OABSS (for both concentrations)</td>
<td>AUR 1.9% (SOL 5 mg); compared with baseline, PVR was significantly increased in both TAM + SOL groups</td>
</tr>
<tr>
<td>Kaplan et al.</td>
<td>12-week, double-blind, randomized, placebo-controlled</td>
<td>192</td>
<td>12 weeks of pbo (62 pts), SOL 6 mg + TAM 0.4 mg (68 pts), or SOL 9 mg + TAM 0.4 mg (62 pts)</td>
<td>PVR, Q&lt;sub&gt;max&lt;/sub&gt;, P&lt;sub&gt;det&lt;/sub&gt; Q&lt;sub&gt;max&lt;/sub&gt;, BCI, BVE, IPSS, PPBC, ICIQ-MaleLUTS, ICIQ-LUTSSol, voided volume/micturition, daily micturitions, daily urgency episodes, daily incontinence episodes</td>
<td>vs Pbo; Noninferior for P&lt;sub&gt;det&lt;/sub&gt; Q&lt;sub&gt;max&lt;/sub&gt; and Q&lt;sub&gt;max&lt;/sub&gt; improvement in frequency and voided volume vs baseline; P&lt;sub&gt;det&lt;/sub&gt; Q&lt;sub&gt;max&lt;/sub&gt; lower for TAM + SOL 6 mg; increase in Q&lt;sub&gt;max&lt;/sub&gt; for both TAM + SOL groups</td>
<td>AUR 0.5% in TAM + SOL; combination groups had significant PVR change at EoT vs pbo</td>
</tr>
<tr>
<td>Lee et al.</td>
<td>12-week, randomized, no placebo</td>
<td>156</td>
<td>Initial phase: 4 weeks of TAM 0.2 (80 pts) or 4 weeks of TAM 0.2 mg plus SOL 5 mg (76 pts) Second phase: 8 weeks of TAM 0.2 mg plus SOL 5 mg (156 pts)</td>
<td>PVR, Q&lt;sub&gt;max&lt;/sub&gt;, IPSS, QoL, OABSS, PPBC, daily urgency episodes</td>
<td>4th week vs TAM: improvement in storage IPSS and QoL 12th week within each group, improvements in storage IPSS, OABSS, and urgency between 4th and 12th week vs baseline; Improvements in storage IPSS, OABSS, nocturia episodes, urgency episodes in patients with decreased nocturnal bladder capacity</td>
<td>AUR: one patient after addition of SOL</td>
</tr>
<tr>
<td>Shin et al.</td>
<td>12-week, randomized, no placebo</td>
<td>405</td>
<td>4 weeks wash-out before enrollment 4 weeks of TAM 0.2 mg, then 4 weeks of TAM 0.2 mg + SOL 5 mg, then 4 weeks of TAM 0.2 mg + desmopressin 0.2 mg; or 4 weeks of TAM 0.2 mg, then 4 weeks of TAM 0.2 mg + desmopressin 0.2 mg, then 4 weeks of TAM 0.2 mg + SOL 5 mg</td>
<td>PVR, Q&lt;sub&gt;max&lt;/sub&gt;, IPSS, OABSS</td>
<td>4th week vs TAM: improvement in storage IPSS and QoL 12th week within each group, improvements in storage IPSS, OABSS, and urgency between 4th and 12th week vs baseline; Improvements in storage IPSS, OABSS, nocturia episodes, urgency episodes in patients with decreased nocturnal bladder capacity</td>
<td>AUR: one patient after addition of SOL</td>
</tr>
</tbody>
</table>
Randomization to storage or voiding group
4 weeks of TAM 0.2 mg or 4 weeks of TAM 0.2 mg + SOL 5 mg
2 week placebo run-in period
12-week treatment period with placebo (92 pts), SOL 3 mg (43 pts), SOL 6 mg (43 pts), SOL 9 mg (44 pts), TAM 0.4 mg (179 pts), TAM 0.4 mg + SOL 3 mg (180 pts), TAM 0.4 mg + SOL 6 mg (180 pts) and TAM 0.4 mg + SOL 9 mg (176 pts)

Post hoc analysis in moderate-to-severe storage symptoms:
Storage IPSS, frequency, urgency, QoL, voided volume, TUFFS, and PPBC improved vs TAM monotherapy

Minor PVR increase, clinically insignificant and irrelevant with the low AUR rates observed

**Notes:** Only statistically significant results are provided.

**Abbreviations:** pts, patients; TAM, tamsulosin; SOL, solifenacin; pbo, placebo; PVR, postvoid residual; Qmax, maximum urinary flow rate; PPBC, patient perception of bladder capacity; UPS, Urgency Perception Scale; IPSS, International Prostate Symptom Score; AUR, acute urinary retention; QoL, quality of life; OABSS, Overactive Bladder Symptom Score; PPIS, Patient Perception of Intensity of Urgency Scale; PPILUTS, Patient Perception of Intensity of Urgency Scale; BCI, Bladder Contractile Index; BVE, bladder voiding efficiency; ICQ-MaleLUTS, Incontinence Questionnaire – Male Lower Urinary Tract Symptoms score; ICQ-LUTSpil, ICQ-LUTS quality-of-life score; EoT, end of treatment; PPIUS, Patient Perception of Intensity of Urgency Scale; TUFFS, Total Urgency and Frequency Score.
study showed that tamsulosin/solifenacin combinations were noninferior to placebo for $Q_{\text{max}}$ and $P_{\text{det}}Q_{\text{max}}^*$ at the end of the trial. While PVR was significantly increased in both combination groups, AUR rate was low. Similarly, the majority of reported adverse events were graded as mild or moderate. At the end of treatment, secondary efficacy end points analysis showed that micition frequency and voided micition volumes were significantly improved in both solifenacin groups versus placebo group.

Efficacy and safety of tamsulosin plus solifenacin combination as initial treatment were evaluated in Korean men with BPH and OAB symptoms. According to the study protocol, patients received either tamsulosin 0.2 mg monotherapy or tamsulosin 0.2 mg plus solifenacin 5 mg. After 4 weeks, both groups received combination therapy. Results from the initial phase of the trial showed that patients receiving combination treatment experienced better improvement in storage symptoms and QoL, compared to patients treated with tamsulosin monotherapy. At end of the trial, no difference in storage indices was revealed between the two groups, and both groups experienced significant improvements in storage LUTS compared to baseline. Mild adverse events were observed and AUR rate was low after solifenacin addition. It was concluded that earlier combination treatment led to an early improvement in storage symptoms and QoL in men with BPH and OAB symptoms.

Shin et al conducted a trial that studied the efficacy and safety of an anticholinergic and an antidiuretic agent as add-on therapy for refractory nocturia in men with BPH treated with tamsulosin. Nocturnal voiding disorders were categorized as nocturnal polyuria, decreased nocturnal bladder capacity, or nocturia caused by both causes. The trial design is presented in Table 1. Subanalysis of study results showed that in both groups, solifenacin addition to tamsulosin therapy led to improvement in storage IPSS and frequency of nocturia and urgency episodes if decreased nocturnal bladder capacity was the main underlying cause.

Yun et al investigated whether men with LUTS can be treated initially with tamsulosin monotherapy or combined with solifenacin, based on patients' reported most bothersome symptom. Patients were categorized into storage (60% of participants) and voiding (40%) groups, based on the most bothersome symptoms among the IPSS items. In each group, patients were randomized to receive tamsulosin monotherapy or combination therapy of tamsulosin plus solifenacin. In terms of IPSS and QoL improvement, storage group benefited more from combination therapy, while voiding group benefited from monotherapy with tamsulosin.

All aforementioned studies evaluated a combination of tamsulosin and solifenacin as initial combination, or add-on therapy, for controlling LUTS in men with BPE/BPH. However, only two studies assessed the use of FDC tablet of solifenacin and tamsulosin in men with LUTS: the Phase III NEPTUNE and NEPTUNE II studies.13,

The NEPTUNE trial was a double-blind Phase III study aiming to evaluate the safety and efficacy of 12-week treatment with two different tamsulosin and solifenacin FDCs in comparison with placebo and tamsulosin monotherapy in 1,334 men with combined moderate- or severe voiding and storage LUTS. Combinations of tamsulosin/solifenacin used were 0.4/6 or 0.4/9 mg. The two primary efficacy variables were the total IPSS and the Total Urgency and Frequency Score (TUFS). According to the study results, the 0.4/6 mg FDC was superior to placebo and noninferior to tamsulosin monotherapy in reducing mean total IPSS score, and superior to tamsulosin in reducing mean TUFS. Compared with tamsulosin, both doses of FDCs led to significant improvements in the IPSS storage subscore, micition frequency, mean voided volume per micition, and QoL parameters, as a result of solifenacin properties (Table 2). It has to be noted that 0.4/9 mg FDC was not found to offer additional benefits, compared with the effects of 0.4/6 mg FDC, which is attributed (by the authors) to a possible plateau effect.

Overall, 30.1% of patients reported AEs during treatment with FDC. Most AEs were considered unrelated to the study medication by the investigators. Drug-related AEs were more frequent with FDCs than with placebo or tamsulosin OCAS (Table 2). The incidence of AUR requiring catheterization in NEPTUNE population was 0.3% in 0.4/6 mg FDC, 0.9% in 0.4/9 mg FDC, and 0.3% in tamsulosin monotherapy. At the same time, minor increases in PVR volume were observed in both FDC groups, judged, however, to be clinically insignificant and not associated with AUR rates. As a general conclusion, NEPTUNE showed that 12-week treatment with 0.4/6 mg FDC offered benefits in patients with moderate or severe storage and voiding LUTS.

In order to evaluate the long-term safety and efficacy of tamsulosin plus solifenacin FDC, patients who completed the NEPTUNE trial were offered to continue into the 40-week NEPTUNE II study. NEPTUNE II was an open-label, flexible-dose, extension study. All patients started with 0.4/6 mg FDC for 4 weeks, and then patients could opt to change to 0.4/9 mg FDC or remain at 0.4/6 mg FDC. According to the study protocol, all patients could request the dose switch at any following visit, without restrictions. Total IPSS score was reduced by 9.0 points over the trial duration, indicating a significant and sustained improvement in symptoms reported by patients. A significant 10.1-point reduction in TUFS was also achieved with treatment of up to 52 weeks,
### Table 2 Characteristics and results of studies on tamsulosin/solifenacin FDC

<table>
<thead>
<tr>
<th>Author</th>
<th>Type of study</th>
<th>Number of participants</th>
<th>Trial design</th>
<th>Outcome measures</th>
<th>Efficacy</th>
<th>Changes in primary efficacy variables from baseline to EoT</th>
<th>Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td>van Kerrebroeck et al (NEPTUNE)</td>
<td>12-week, double-blind, randomized, placebo controlled</td>
<td>1,328</td>
<td>2-week placebo run-in period, 12-week treatment period with placebo (341 pts), TAM 0.4 mg (327 pts), TAM 0.4 mg + SOL 6 mg (339 pts) and TAM 0.4 mg + SOL 9 mg (327 pts)</td>
<td>IPSS, TUFs, Q_{max}, Q_{ave}, PVR, voided volume/micturition, daily micturition frequency, urgency episodes, nocturia, use of pads, QoL, OAB-q, HRQoL, PGI, CGI</td>
<td>Significant improvements versus placebo for both TAM + SOL combinations in total and storage IPSS, TUFs, QoL, PGI, CGI, OAB-q. HRQoL, frequency, voided volume and urgency episodes. TAM + SOL 6 mg was superior to TAM for total IPSS, TUFs, and frequency improvement. Both combinations were superior to TAM for storage IPSS, voided volume, and several QoL variables</td>
<td>Total IPSS: Pbo: -5.4±0.41 TAM: -6.2±0.42 TAM + SOL 6 mg: -7.0±0.41 TAM + SOL 9 mg: -6.5±0.42 TUFs: Pbo: -4.4±0.68 TAM: -6.7±0.69 TAM + SOL 6 mg: -8.1±0.67 TAM + SOL 9 mg: -7.6±0.69</td>
<td>AUR: 0.3% in TAM + SOL 6 mg, 0.9% in TAM + SOL 9 mg. PVR increases with both combinations were clinically insignificant</td>
</tr>
<tr>
<td>Drake et al* (NEPTUNE II)</td>
<td>40-week, open-label, flexible-dosing</td>
<td>1,066</td>
<td>40 weeks of treatment with TAM 0.4 mg plus SOL 6 or 9 mg</td>
<td>IPSS, TUFs, Q_{max}, Q_{ave}, PVR, voided volume/micturition, daily micturition frequency, urgency episodes, QoL, OAB-q</td>
<td>Q_{max} and Q_{ave} were increased at EoT. Total, storage and voiding IPSS and TUFs, as well as frequency, urgency, and incontinence episodes were improved at the EoT. QoL parameters were reported improved at EoT</td>
<td>Total IPSS: -9.0±5.70 TUFs: -10.1±9.20</td>
<td>Small PVR increase was observed; however, AUR rate was 0.7% in total</td>
</tr>
</tbody>
</table>

**Abbreviations:** EoT, end of treatment; pts, patients; TAM, tamsulosin; SOL, solifenacin; pbo, placebo; PVR, post-void residual; Q_{max}, maximum urinary flow rate; Q_{ave}, average flow rate; OAB-q, overactive bladder questionnaire; HRQoL, health-related quality-of-life questionnaire; PGI, Patient Global Impression scale; CGI, Clinician Global Impression scale; IPSS, International Prostate Symptom Score; AUR, acute urinary retention; QoL, quality of life; TUFs, Total Urgency and Frequency Score; FDC, fixed dose combination.
confirming sustained improvements observed in both urinary urgency and frequency. Patient satisfaction and QoL were also improved, a finding mainly attributed to storage symptoms improvement. $Q_{\text{max}}$, volume of micturitions, urgency, incontinence episodes, and voided volume per micturition were found to be improved at the end of treatment in comparison to baseline, while a small increase in PVR was revealed (Table 2). While almost half the patients (46.8%) experienced treatment-emergent adverse events, most of them were mild or moderate in severity. Observed AUR rate in NEPTUNE II was 0.7%, even though 50% of study participants were in high risk for AUR due to prostate enlargement at baseline estimation. Of those ending the study on 0.4/6 mg FDC, 87.7% were satisfied with its safety and 87.0% were satisfied with its efficacy, versus 85.8% and 73.3%, respectively, for those ending the study on 0.4/9 mg FDC. When asked which dose they would have taken had the study continued, 681 (70.2%) indicated 0.4/6 mg FDC and 289 (29.8%) indicated 0.4/9 mg FDC. The majority of patients (70.2%) would have selected 0.4/6 mg FDC as the preferred treatment if the study had continued, because no additional benefit was found with the 0.4/9 mg FDC, whereas fewer patients were satisfied with its safety.

Therefore, NEPTUNE II provided evidence on the safety and efficacy of 0.4/6 mg FDC in the management of moderate-to-severe LUTS in men with BPE/BPH. The main characteristics and outcomes of studies using the FDC are presented in Table 2.

A wide heterogeneity is observed in the available studies on tamsulosin plus solifenacin in terms of the studied populations, the outcome measures, the doses of tamsulosin or solifenacin used, the duration and design of therapeutic protocol, and the external validity of obtained results. The vast majority of studies are of short duration, in contrast with the long-term medical treatment required in real clinical practice. Therefore, issues of patient adherence to therapy and long-term safety and efficacy of the combination treatment are raised. Studies conducted in Asian populations used tamsulosin 0.2 mg in contrast to the commonly used dose of 0.4 mg, while large discrepancies are also revealed in the dose of solifenacin used, as doses of 3, 5, 6, and 9 mg were used and compared in different studies. Finally, the noninferiority design selected in some of the major studies dictates the need to evaluate the findings with caution.

Patients’ nonadherence to medical treatment of male LUTS represents a significant problem. It has been found that combination therapies result in better compliance compared to monotherapies. In addition, it has been shown that less frequent dosage enhances adherence, and technical adherence interventions are usually directed at simplifying the medication regimen. Therefore, a potential advantage of the FDC of solifenacin/tamsulosin may be the improvement of patients’ adherence.

**Conclusion**

Current guidelines suggest the use of combination treatment ($\alpha$-blocker and antimuscarinic) in patients with bothersome LUTS, if storage symptoms relief has been insufficient with monotherapy with either drug. Efforts have been made to develop algorithms in order to assist clinicians to select those patients who will benefit more from the combination therapy. In accordance with previous studies on the separate administration of solifenacin and tamsulosin, data on the tamsulosin OCAS 0.4 mg with solifenacin 6 mg FDC showed that FDC results in significant amelioration of storage symptoms and improvement in overall QoL in men with storage and voiding LUTS, compared to tamsulosin monotherapy. FDC was well tolerated without significantly increasing the risk of AUR despite an increase in PVR.

Yet more large-scale studies on tamsulosin/solifenacin FDC for the management of storage and voiding LUTS in men with BPH are required, as long-term follow-up data are lacking, and methodological discrepancies exist in the available studies. In addition, issues of optimal patient selection, patients’ adherence, and cost of treatment also need to be investigated.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


